UPB (Upstream Bio) YoY EPS Growth: 2.11% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UPB Upstream Bio Inc UPB
12 GF Score
Price $5.48
! 3 Warning Signs
View Full Analysis

What is Upstream Bio YoY EPS Growth?

Upstream Bio UPB -5.68% 12 YoY EPS Growth is 2.11% as of Jun. 2026. GuruFocus rates UPB with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Upstream Bio's YoY EPS Growth for the quarter that ended in Jun. 2026 was 2.11%.

Upstream Bio's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.73.

Upstream Bio YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Upstream Bio's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Upstream Bio YoY EPS Growth Chart

Upstream Bio Annual Data
Trend Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
0.00 -60.27 -99.69 -86.89

Upstream Bio Quarterly Data
Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial 0.00 -59.48 -93.28 -46.95 2.11
UPB
12GF Score
Upstream Bio Inc UPB
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Upstream Bio YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Upstream Bio's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-2.6636--1.4252)/ | -1.4252 |
=-86.89 %

Upstream Bio's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.7276--0.7433)/ | -0.7433 |
=2.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 2.11% mean?
Upstream Bio (UPB) has a YoY EPS Growth of 2.11% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Upstream Bio and its competitors.
Is Upstream Bio's YoY EPS Growth too high?
Upstream Bio's current YoY EPS Growth is 2.11%. Overall, Upstream Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Upstream Bio's YoY EPS Growth compare to IPSC and ZNTL?
Upstream Bio's YoY EPS Growth of 2.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Upstream Bio and its competitors. Upstream Bio's current YoY EPS Growth is 2.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Upstream Bio stock overvalued right now?
Upstream Bio (UPB) has a current YoY EPS Growth of 2.11%. The current YoY EPS Growth is 2.11%. Upstream Bio's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Upstream Bio (UPB), the current YoY EPS Growth is 2.11% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Upstream Bio Business Description

Address 890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
12GF Score

Get the complete analysis for UPB

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.48
Price